Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab dose-ranging phase 3 study in active Sjögren's syndrome
CTR20223003Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Started Aug 2023; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on CTR20223003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223003.